The measurement of serum thyroid hormones, including TSH, FT3 and FT4, was performed by using an electrochemiluminescence immunoassay with a Cobas Elecsys 411 (Roche Diagnostics, Mannheim, Germany), coupled with corresponding calibration materials, reagents and quality controls. The quality control procedure was carried out according to the manufacturer’s instructions and standards. To ensure the reliability of the results, all samples were analyzed after testing the quality control samples. The limits of detection (LODs) for TSH, FT3 and FT4 were 0.005 mIU/L, 0.6 pmol/L and 0.5 pmol/L, respectively. Among the studied serum samples, the detection rates of FT3 and FT4 were 100%. Meanwhile, the TSH concentrations of 7 samples were below the LOD. All of these observations below the LOD were substituted by LOD/2.
Cobas elecsys 411
Manufactured by Roche
The Cobas Elecsys 411 is an automated immunoassay analyzer designed for clinical laboratory testing. It is used to perform a variety of immunoassay tests, including those for hormones, therapeutic drug monitoring, and infectious disease detection. The Cobas Elecsys 411 offers high-throughput capabilities and is intended for use in clinical settings.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using cobas elecsys 411
1
Serum Thyroid Hormone Measurement
2
Monitoring Patients During Hepatitis B Treatment
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
During PEG‐IFN treatment, routine examination and laboratory testing were performed every 4 weeks. After PEG‐IFN treatment was stopped, patients visited the out‐patient clinic every 12 weeks until EOF. Patients on ETV monotherapy had study visits every 12 weeks throughout the entire study period. Routine biochemical and haematological tests were assessed locally at every visit. Serum ALT levels were standardised according to the ULN per centre and gender. Serum HBV DNA was measured with the Cobas TaqMan 48 polymerase chain reaction assay (lower limit of detection: 20 IU/mL; Roche Diagnostics, Basel, Switzerland). Serum HBeAg, anti‐HBe and HBsAg were evaluated with Architect (Abbott Laboratories, North Chicago, IL) or Cobas Elecsys 411 (lower limit of detection 0.30 and 0.05 IU/mL, respectively; Roche Diagnostics). HBV genotyping was performed with the INNO‐LiPA HBV genotype assay (Fujirebio Europe, Ghent, Belgium). If HBV genotype could not be assessed due to undetectable HBV DNA levels at baseline, we reviewed HBV genotype data in medical charts where possible. The presence of cirrhosis was defined by Ishak stage 6 on liver biopsy, or an aspartate aminotransferase to platelet ratio index (APRI) score >1.0.24
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!